CM
TBPH icon

Caption Management’s Theravance Biopharma TBPH Stock Holding History

Caption Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-163,704
Closed -$2.66M – 2034
2026
Q1 		$2.66M Buy
+163,704
New +$2.9M 0.02% 741
2023
Q1 		– Sell
-82,000
Closed -$920K – 1534
2022
Q4 		$920K Buy
82,000
+22,000
+37% +$231K 0.01% 774
2022
Q3 		$608K Buy
+60,000
New +$562K 0.01% 1020
2022
Q2 		– Sell
-31,800
Closed -$304K – 1820
2022
Q1 		$304K Buy
+31,800
New +$312K ﹤0.01% 1212
2020
Q4 		– Sell
-4,400
Closed -$65K – 1235
2020
Q3 		$65K Sell
4,400
-2,017
-31% -$37.8K ﹤0.01% 963
2020
Q2 		$135K Buy
+6,417
New +$165K ﹤0.01% 821
2019
Q3 		– Sell
-80,000
Closed -$1.31M – 882
2019
Q2 		$1.31M Buy
80,000
+67,500
+540% +$1.37M 0.07% 323
2019
Q1 		$284K Buy
+12,500
New +$317K 0.02% 487

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caption Management's TBPH Position: Q2 2026 in Review

Caption Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 163,704 shares — an estimated $2.66M sold.

Caption Management first reported a position in TBPH in Q1 2019 and held it in 8 quarters. The position peaked at $2.66M in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Caption Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 163,704 Theravance Biopharma shares in Q2 2026, an estimated $2.66M.
  • Caption Management first reported a position in Theravance Biopharma in Q1 2019 and held it in 8 quarters.
  • Caption Management's Theravance Biopharma position peaked at $2.66M in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.